Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03996265 · ClinicalTrials.gov registry record · Phase 3
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
A Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by University of Rochester NCORP Research Base.
- Active
- Registry status
- Phase 3
- Development phase
- 422
- Enrollment target
- 20
- Study locations
NCT03996265 is a Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm that is active but no longer recruiting, run by University of Rochester NCORP Research Base. The registered enrollment target is 422 participants, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT03996265, a Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, is active but no longer recruiting, sponsored by University of Rochester NCORP Research Base.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 422 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- DRUG Bupropion Hydrochloride Controlled-release
- OTHER Placebo Administration
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- PCR Oncology - Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fremont - Fremont
- Fresno Cancer Center - Fresno
- Kaiser Permanente-Fresno - Fresno
- Contra Costa Regional Medical Center - Martinez
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CARTI Cancer Center - Little Rock
Arizona
- Kingman Regional Medical Center - Kingman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2026-08-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03996265
The ClinicalTrials.gov registry entry for NCT03996265 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 422 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (63% lower). The listed sponsor is University of Rochester NCORP Research Base, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT03996265 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alaska, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03996265 about?
NCT03996265 is a clinical study titled "Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors". This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepress...
What is the current status of trial NCT03996265?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 422 participants. The study started on 2019-06-27. Estimated completion is 2026-08-05.
What conditions does trial NCT03996265 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm.
What interventions are being tested in trial NCT03996265?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Bupropion Hydrochloride Controlled-release (DRUG), Placebo Administration (OTHER).
Who is sponsoring clinical trial NCT03996265?
This trial is sponsored by University of Rochester NCORP Research Base, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03996265 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
RECRUITING · Phase 3
-
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
RECRUITING · Phase 3
-
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
RECRUITING · Phase 3
-
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
RECRUITING · Phase 3
Explore more on PlainTrial
Malignant Solid Neoplasm
All registered trials for this condition
Hematopoietic and Lymphatic System Neoplasm
All registered trials for this condition
Alaska
All trials with a study site in Alaska
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.